Advantages
- Distinct BAC backbone allows for transgene integration on a separate chromosome, avoiding linkage and complex breeding schemes observed in current strains.
- Demonstrates >90% Cre-mediated excision in Prox1+ lymphatic endothelial cells, outperforming previous models which demonstrate ~60-70%.
- Restricts recombination to lymphatic vasculature and avoids off-target effects unlike previous lines which also target blood endothelium or macrophages.
- SV40 stop signal downstream of CreERT2 prevents transcriptional read through, reducing leakiness compared to broader inducible drivers.
Summary
Our inventors have developed a novel BAC transgenic Prox1CreERT2 mouse line with chromosomal integration distinct from prior strains, facilitating simpler breeding strategies and avoiding recombination conflicts. This line achieves >90% expression of tamoxifen-inducible CreERT2 under the promoter of the gene, Prox1, thus enabling the user to efficiently delete any gene that is flanked by loxP sites in Prox1-expressing cells in vivo. One application where this strain will be useful will be to delete genes in the lymphatic vasculature while avoiding deletion in blood vessels.
Desired Partnership